Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase II umbrella trial assessing the anti-tumor activity of
enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic
castration-resistant prostate cancer. The trial will open to enrollment in Cohort A,
enfortumab monotherapy. Additional cohorts may be added as new drug combinations are
identified.